Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Palisade Bio is a pre-clinical stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead product candidate, PALI-2108, is a PDE4 inhibitor being developed for inflammatory bowel disease (IBD). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(4,080) | $(7,607) | N/A |
| Operating Expenses | $(4,211) | $(7,884) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $11,353 |
| Total Assets | N/A | N/A | $12,871 |
| Total Liabilities | N/A | N/A | $2,922 |
| Stockholders' Equity | N/A | N/A | $9,949 |
| Accumulated Deficit | N/A | N/A | $(129,113) |
Per Share Data: Basic and diluted net loss per common share was $(3.32) for the three months ended June 30, 2024, and $(7.60) for the six months ended June 30, 2024. These figures reflect a 1-for-15 reverse stock split effected on April 5, 2024.
Material Changes vs. Prior Period
- Revenue: The company recognized no license revenue for the three or six months ended June 30, 2024, compared to $250,000 in license revenue recognized in the six months ended June 30, 2023 (from a milestone under the Newsoara Co-Development Agreement).
- Operating Expenses: Total operating expenses increased by 17% ($602,000) for the three months ended June 30, 2024, compared to the same period in 2023. This was driven by a 21% increase in Research and Development (R&D) expenses to $2.6 million, primarily due to $1.9 million in joint development costs for PALI-2108 with Giiant Pharma. General and Administrative (G&A) expenses increased by 11% to $1.6 million.
- Net Loss: Net loss increased by 20% ($687,000) for the three months ended June 30, 2024, compared to the prior year period.
- Capital Structure: The company completed a 1-for-15 reverse stock split in April 2024. Outstanding common shares increased from 618,056 at year-end 2023 to 966,345 at June 30, 2024, due to equity issuances.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the issuance of the financial statements. The company has an accumulated deficit of $129.1 million and expects to continue incurring losses. It believes current cash resources ($11.4 million) are sufficient to fund operations through the first quarter of 2025.
- Financing Activity:
- May 2024 Offering: Completed a private placement raising net proceeds of approximately $3.5 million (gross $4.0 million).
- February 2024 Warrant Inducement: Raised net proceeds of approximately $2.2 million through the exercise of existing warrants at a reduced price.
- Development Outlook: The company plans to submit an Investigational New Drug (IND) application in the third quarter of 2024 and initiate Phase 1 clinical trials for PALI-2108 in the fourth quarter of 2024. Topline data is expected in the first half of 2025.
- Subsequent Event: On August 2, 2024, the company amended its license agreement with Giiant Pharma to increase reimbursement advances in exchange for reduced milestone payments and a lower payment cap.
- Internal Controls: The company identified a material weakness in internal control over financial reporting related to the financial closing process and segregation of duties. Remediation efforts are ongoing but the weakness remains as of June 30, 2024.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $11.4 million cash balance to fund operations through Q1 2025, considering the anticipated increase in cash usage for the Phase 1 trial of PALI-2108.
- Capital Requirements: Assess the likelihood and terms of future equity or debt financing required beyond Q1 2025 to continue development.
- Development Milestones: Monitor the timeline for the IND submission (Q3 2024) and Phase 1 trial initiation (Q4 2024) for PALI-2108.
- Internal Controls: Review the progress of remediation efforts regarding the material weakness in internal controls over financial reporting.
- Collaboration Terms: Review the implications of the August 2024 amendment to the Giiant License Agreement on future cash commitments and milestone obligations.